Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

The Impact of Omega-3 Fatty Acid Supplementation on the Composition of Erythrocyte Membranes

3. juni 2026 opdateret af: Małgorzata Magdalena Michalczyk, The Jerzy Kukuczka Academy of Physical Education in Katowice

The Impact of Omega-3 Fatty Acid Supplementation on the Composition of Erythrocyte and Neuromuscular System in Athletes

Therefore, the aim of our project will be to assess the impact of omega-3 fatty acid on the neuromuscular system (muscle tensomyography- TMG), the composition and fluidity of erythrocyte cell membranes, the lipid profile and the antioxidant status of the blood.

Studieoversigt

Status

Tilmelding efter invitation

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

The ability of skeletal muscles to generate force and resist fatigue is essential for athletic performance. Training adaptations within the neuromuscular system and skeletal muscles modulate the muscles' ability to produce force and resistance to fatigue. Much research has been conducted to determine the effects of dietary supplements on skeletal muscle adaptation to strength training (e.g., protein supplementation) and methods to support endurance performance (e.g., carbohydrate loading). However, limited research has been conducted to date on the effects of dietary supplements on the neuromuscular system.The research will focus on the effect of 4 and 8 weeks of supplementation with high doses of omega 3 fatty acids on the level of omega 3/omega6 fatty acids, the level of TRANS fatty acids and AA (arachidonic acid) fatty acid using a mixed diet. Additionally, we will examine the effect of this supplementation on the neuromuscular system (muscle tensomyography -TMG), the composition and fluidity of erythrocyte cell membranes, the lipid profile and the antioxidant status of the blood. The research will use innovative assumptions - high doses of omega 3 fatty acids. Additionally, a new laboratory tool will be used to assess the level of individual fatty acids (omega 3, omega 6) in the blood, the level of which shows or excludes latent inflammation in the body.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

200

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

  • Polen
      • Katowice, Polen, 40-065
        • Academy of Physical Education in Katowice

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen

Tager imod sunde frivillige

Ja

Beskrivelse

**Inclusion Criteria:**

  • Male participants aged 20-40 years.
  • Apparently healthy individuals, as determined by medical history and self-reported health status.
  • Physically active, engaging in regular physical activity at least 3 times per week for the previous 6 months.
  • Following a mixed diet.
  • Willingness to maintain habitual dietary and physical activity patterns throughout the study.
  • Willingness to refrain from consuming dietary supplements other than those provided as part of the study.

**Exclusion Criteria:**

  • Current use of dietary supplements within 4 weeks prior to enrollment.
  • Following a low-carbohydrate, ketogenic, high-carbohydrate, vegetarian, or vegan diet.
  • Presence of gastrointestinal disorders affecting nutrient absorption, including irritable bowel syndrome, inflammatory bowel disease, celiac disease, or other clinically significant gastrointestinal conditions.
  • History of cardiovascular, metabolic, endocrine, hepatic, renal, neurological, or autoimmune diseases.
  • Current use of medications known to affect lipid metabolism, inflammation, antioxidant status, or cognitive function.
  • Known allergy or intolerance to study supplements or their ingredients.
  • Participation in another clinical trial within the previous 3 months.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Diagnostisk
  • Tildeling: Randomiseret
  • Interventionel model: Crossover opgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: AL (Alpha-linolenic acid) supplementation
Participants were randomly assigned to the ALA supplementation group. After 4 weeks of the supplementation, there was a 12-week wash-out period, after which the participants crossed over to the EPA /DHA group.
Kosttilskud: ALA supplements
The supplement will be administered in a dose of 4 capsules twice a day for 4 weeks. Daily dose will contain 3500mg ALA.
Eksperimentel: EPA (eicosapentaenoic acid)/DHA (docosahexaenoic acid) supplementation
Participants were randomly assigned to the EPA/DHA supplementation group. After 4 weeks of the supplementation, there was a 12-week wash-out period, after which the participants crossed over to the ALA group.
Kosttilskud: EPA/DHA supplements
The supplement will be administered in a dose of 4 capsules twice a day for 4 weeks. Each capsule will contain 330mg EPA and 220mgDHA.
Andre navne:
  • Placebo tilskud
  • EPA/DHA supplementation
  • ALA supplementation
Placebo komparator: Placebo supplementation
Participants were randomly assigned to the Placebo group. After 4 weeks of the supplementation, there was a 12-week wash-out period, after which they repeated the placebo supplementation.
Kosttilskud: Placebo supplements
The supplement will be administered in a dose of 4 capsules twice a day for 4 weeks. One capsule will contain 550 mg of olive oil. The placebo will be matched to the supplement in appearance.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Omega 3 index
Tidsramme: 4-weeks

The Omega-3 Index (%) determines the content of EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) relative to total fatty acids in erythrocyte membranes. It is expressed as a percentage and reflects long-term fatty acid intake.

Unit of Measure: %
4-weeks

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Tensiomyography (TMG) Parameters
Tidsramme: 4-weeks
2a. Maximal Radial Displacement (Dm) Unit of Measure: mm 2b. Contraction Time (Tc) Unit of Measure: ms 2c. Delay Time (Td) Unit of Measure: ms 2d. Sustain Time (Ts) Unit of Measure: ms 2e. Half-Relaxation Time (Tr) Unit of Measure: ms Description: Muscle contractile properties assessed using tensiomyography (TMG-BMC system).
4-weeks
Corsi Block-Tapping Test - Unweighted Block Span
Tidsramme: 4-weeks

Description: Maximum correctly reproduced sequence length in Corsi Block-Tapping Test.

Unit of Measure: blocks
4-weeks
Corsi Block-Tapping Test - Block Time
Tidsramme: 4 weeks

Description: Reaction time performance in visuospatial working memory assessed using Corsi Block-Tapping Test.

Unit of Measure: ms
4 weeks
Corsi Block-Tapping Test - Reverse Span Score
Tidsramme: 4 weeks

Description: Working memory performance assessed using reverse span condition of Corsi Block-Tapping Test.

Unit of Measure: score
4 weeks

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Total Antioxidant Status (TAS)
Tidsramme: 4 weeks

Description: Plasma total antioxidant status measured using Randox TAS kit.

Unit of Measure: mmol/L
4 weeks
Malondialdehyde (MDA) Concentration
Tidsramme: 4 weeks

Description: Plasma malondialdehyde concentration measured using thiobarbituric acid reactive substances method.

Unit of Measure: nmol/mL
4 weeks
Superoxide Dismutase (SOD) Activity
Tidsramme: 4 weeks

Description: Activity of superoxide dismutase in red blood cell lysates measured using Randox kits.

Unit of Measure: U/g Hb
4 weeks
Glutathione Peroxidase (GPx) Activity
Tidsramme: 4 weeks

Description: Activity of glutathione peroxidase in red blood cell lysates measured using Randox kits.

Unit of Measure: U/g Hb
4 weeks
Body Mass
Tidsramme: 4 weeks

Description: Body mass measured using multi-frequency bioelectrical impedance analysis (InBody 770).

Unit of Measure: kg
4 weeks
Body Fat Percentage
Tidsramme: 4 weeks

Description: Body fat percentage measured using multi-frequency bioelectrical impedance analysis (InBody 770).

Unit of Measure: %
4 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

The Jerzy Kukuczka Academy of Physical Education in Katowice

Efterforskere

  • Studieleder: Małgorzata Magdalena Michalczyk, Phd, Institute of Sport Sciences, Jerzy Kukuczka Academy of Physical Education in Katowice

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

15. april 2025

Primær færdiggørelse (Faktiske)

25. februar 2026

Studieafslutning (Anslået)

31. december 2027

Datoer for studieregistrering

Først indsendt

18. maj 2026

Først indsendt, der opfyldte QC-kriterier

3. juni 2026

Først opslået (Faktiske)

8. juni 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

8. juni 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

3. juni 2026

Sidst verificeret

1. maj 2026

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Andre undersøgelses-id-numre

  • 4-II/2024
  • 2024/53/B/NZ7/02257 (Andet bevillings-/finansieringsnummer: Narodowe Centrum Nauki)
  • RID/SP/0053/2024/01 (Anden identifikator: The Regional Initiative of Excellence programme)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Anonymised data will be available upon reasonable request.

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med ALA supplements

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Cameroon

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

Abonner